Literature DB >> 8329711

Identification of immature and mature myeloma cells in the bone marrow of human myelomas.

M M Kawano1, N Huang, H Harada, Y Harada, A Sakai, H Tanaka, K Iwato, A Kuramoto.   

Abstract

With regard to the expression of adhesion molecules, human myeloma cells freshly isolated from bone marrow were heterogeneous. By two-color analysis with anti-VLA-5 antibody (PE staining) and FITC-labeled anti-CD38 antibody, we found all myeloma cells located at CD38-strong positive (CD38++) fraction and identified two subpopulations among these myeloma cells: CD38++ VLA-5-(VLA-5-) myeloma cells and CD38++ VLA-5+ (VLA-5+) myeloma cells. To clarify the biologic character of these two subpopulations, the morphology, in vitro proliferative activity and in vitro M-protein secretion were examined in each fraction isolated by the purification procedure or a cell sorter. Morphologic examination showed that VLA-5- myeloma cells were mostly immature or plasmablastic and VLA-5+ cells were mature myeloma cells. Furthermore, VLA-5- myeloma cells proliferated markedly in vitro and responded to interleukin 6 (IL-6), a growth factor for myeloma cells, while VLA-5+ myeloma cells showed very low uptakes of 3H-thymidine and no responses to IL-6 but secreted higher amounts of M-protein (immunoglobulin) in vitro significantly. Therefore, we could clarify here heterogeneity of human myeloma cells in the bone marrow with regard to the expression of VLA-5, one of integrin adhesion molecules; VLA-5- myeloma cells were proliferative immature cells and VLA-5+ cells were mature myeloma cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8329711

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

1.  Establishment of an HS23 stromal cell-dependent myeloma cell line: fibronectin and IL-6 are critical.

Authors:  Akira Sakai; Miyo Oda; Mitsuhiro Itagaki; Noriaki Yoshida; Koji Arihiro; Akiro Kimura
Journal:  Int J Hematol       Date:  2010-10-06       Impact factor: 2.490

2.  Unfolded protein response inducers tunicamycin and dithiothreitol promote myeloma cell differentiation mediated by XBP-1.

Authors:  Hua Jiang; Jianfeng Zou; Hui Zhang; Weijun Fu; Tianmei Zeng; Hejing Huang; Fan Zhou; Jian Hou
Journal:  Clin Exp Med       Date:  2013-12-20       Impact factor: 3.984

3.  Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.

Authors:  Deepika Sharma Das; Abhishek Das; Arghya Ray; Yan Song; Mehmet Kemal Samur; Nikhil C Munshi; Dharminder Chauhan; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2017-03-07       Impact factor: 12.531

4.  Growth mechanism of human myeloma cells by interleukin-6.

Authors:  Michio M Kawano; Hideaki Ishikawa; Naohiro Tsuyama; Saeid Abroun; Shangqin Liu; Fu-Jun Li; Ken-ichiro Otsuyama; Xu Zheng
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

5.  A reappraisal of immunoglobulin variable gene primers and its impact on assessing clonal relationships between PB B cells and BM plasma cells in AL amyloidosis.

Authors:  Nagaaki Katoh; Tanya L Poshusta; Michelle K Manske; Angela Dispenzieri; Morie A Gertz; Roshini S Abraham; Marina Ramirez-Alvarado
Journal:  J Clin Immunol       Date:  2011-09-10       Impact factor: 8.317

Review 6.  Immunotherapies targeting CD38 in Multiple Myeloma.

Authors:  Djordje Atanackovic; Mary Steinbach; Sabarinath Venniyil Radhakrishnan; Tim Luetkens
Journal:  Oncoimmunology       Date:  2016-08-05       Impact factor: 8.110

7.  Establishment of a monoclonal antibody to plasma cells: a comparison with CD38 and PCA-1.

Authors:  H Hata; H Matsuzaki; F Matsuno; T Sonoki; S Takemoto; N Kuribayashi; A Nagasaki; K Takatsuki
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

8.  T cells induce terminal differentiation of transformed B cells to mature plasma cell tumors.

Authors:  D M Hilbert; M Y Shen; U R Rapp; S Rudikoff
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

9.  Aggressive course of primary plasma cell leukemia with unusual morphological and cytogenetic features.

Authors:  J Richter; A Swedin; T Olofsson; B Johansson; M Akerman; I Winqvist
Journal:  Ann Hematol       Date:  1995-12       Impact factor: 3.673

10.  Antigens shared by malignant plasma cells and normal B cells may be involved in graft versus myeloma.

Authors:  P A Holloway; N Kaldenhoven; H M Kok-Schoemaker; B Van Kessel; W T M Van Blokland; A C Bloem; H M Lokhorst
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.